Clevidipine

CHEMBL1237132 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
456.3 g/mol
LogP
4.3
Phase
4

A short-acting calcium channel blocker given intravenously to rapidly lower dangerously high blood pressure, particularly in surgical or critical-care settings. It works by relaxing the muscles in artery walls to reduce vascular resistance.

Masse moléculaire

456,3000 g/mol

LogP

4,30

TPSA

90,90 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl

InChI

InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3

Molecular Formula

C21H23Cl2NO6

HBD / HBA

1 / 7

Liaisons Rotatives

10

Atomes Lourds

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A short-acting calcium channel blocker given intravenously to rapidly lower dangerously high blood pressure, particularly in surgical or critical-care settings. It works by relaxing the muscles in artery walls to reduce vascular resistance.

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Yes, Clevidipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237132. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 153994. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.